98%
921
2 minutes
20
A reliable, sensitive, HPLC method was developed and validated to simultaneously quantify raloxifene (RLX) and cladrin (CLD). The C18 column was used to analyze RLX and CLD at λ 285 and 249 nm. The mobile phase was composed of acetonitrile and 35:65% v/v aqueous solution of 0.1% formic acid. The method was linear over the linearity range of 0.078-20 μg/ml, and the limit of detection and limit of quantification for RLX and CLD were 0.191 and 0.228 and 0.581 and 0.69 μg/ml, respectively. In accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines, the developed method is precise and accurate for simultaneous estimation of RLX and CLD with applications in liver microsomal stability in mice, rabbits, dogs, monkeys and humans.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4155/bio-2023-0046 | DOI Listing |
Bioanalysis
June 2023
Division of Pharmaceutics & Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
A reliable, sensitive, HPLC method was developed and validated to simultaneously quantify raloxifene (RLX) and cladrin (CLD). The C18 column was used to analyze RLX and CLD at λ 285 and 249 nm. The mobile phase was composed of acetonitrile and 35:65% v/v aqueous solution of 0.
View Article and Find Full Text PDFInt J Tissue React
April 2004
Department of Internal Medicine, University of Turin, Turin, Italy.
The aim of the present study was to determine the safety and efficacy of combined therapy with raloxifene (RLX) and clodronate (CLD) in postmenopausal women. We enrolled 45 women with postmenopausal osteoporosis. The patients were randomly assigned to two different therapeutic groups: RLX 60 mg/day (n = 23) and RLX 60 mg/day plus CLD 100 mg intramuscularly (i.
View Article and Find Full Text PDF